Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation.

Diabetes Obes Metab · 2026 · PMC13243989 · PMID 42010367

Europe PMC DOI

hedged sentences

0.0710

closest p · 1.4× alpha

0.0710

boldest claim

The sentences

showed a trendp = 0.071so close (0.05 < p ≤ 0.1)

In the T2D cohort, semaglutide was not associated with osteoporosis risk versus any individual comparator, though the comparison with empagliflozin showed a trend (HR 0.90, 95% CI: 0.81–1.01; p = 0.071).

also in 53,322 other papers

marginal significanceno p-value reported

Associations observed in a single comparison or with marginal significance should be interpreted with greater caution.

also in 5,069 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.